

# Timothy C Hardman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3074161/publications.pdf>

Version: 2024-02-01

62  
papers

1,000  
citations

516561

16  
h-index

454834

30  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.	3.1	8
2	Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. <i>Drugs in Context</i> , 2022, 11, 1-15.	1.0	0
3	Exacerbation Profile and Risk Factors in a Type-2“Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	2.5	14
4	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	2.7	7
5	Action of Dipeptidyl Peptidase“4 Inhibitors on SARS“CoV“2 Main Protease. <i>ChemMedChem</i> , 2021, 16, 1425-1426.	1.6	9
6	Composite type-2 biomarker strategy versus a symptom“risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 57-68.	5.2	88
7	A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. <i>GeroScience</i> , 2021, 43, 1317-1329.	2.1	31
8	How to Interpret an Investigator“™s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 612-618.	0.8	2
9	The effect of azoximer bromide (Polyoxidonium“®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. <i>Drugs in Context</i> , 2021, 10, 1-10.	1.0	3
10	Ten tips for promoting your research. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 30-35.	0.5	3
11	Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma. <i>Pathology</i> , 2020, 52, 538-545.	0.3	7
12	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. <i>Frontiers in Pharmacology</i> , 2020, 11, 580560.	1.6	3
13	The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum. <i>Frontiers in Pharmacology</i> , 2019, 10, 398.	1.6	5
14	Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 721-733.	2.9	98
15	European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development“Be Prepared. <i>Frontiers in Pharmacology</i> , 2019, 10, 1377.	1.6	1
16	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 1301.	1.6	2
17	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. <i>Trials</i> , 2018, 19, 5.	0.7	26
18	Ready! Aim! Fire! targeting the right medical science journal. <i>Cardiovascular Endocrinology</i> , 2017, 6, 95-100.	0.8	10

#	ARTICLE	IF	CITATIONS
19	EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management. <i>Frontiers in Pharmacology</i> , 2017, 8, 901.	1.6	2
20	Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). <i>Thorax</i> , 2016, 71, 187-189.	2.7	78
21	Bariatric surgery in obese older people. <i>Cardiovascular Endocrinology</i> , 2015, 4, 60-66.	0.8	3
22	An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes - the MID-Frail study: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 34.	0.7	65
23	Sarcoidosis: the links between epidemiology and aetiology. <i>Postgraduate Medical Journal</i> , 2014, 90, 582-589.	0.9	51
24	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	0.8	22
25	New therapies in the management of type 2 diabetes mellitus. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 202-207.	0.2	2
26	Drugs in development for the management of dyslipidaemia. <i>Future Prescriber</i> , 2012, 13, 12-15.	0.1	0
27	Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 667-676.	1.9	36
28	New lipid-lowering drugs: an update. <i>International Journal of Clinical Practice</i> , 2012, 66, 270-280.	0.8	61
29	Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. <i>Diabetes Therapy</i> , 2011, 2, 133-145.	1.2	52
30	Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to &#x2018;Sweet Pee&#x2019;. <i>Current Pharmaceutical Design</i> , 2010, 16, 3830-3838.	0.9	15
31	Future Challenges for Microsomal Transport Protein Inhibitors. <i>Current Vascular Pharmacology</i> , 2009, 7, 277-286.	0.8	43
32	HIV lipodystrophy and its metabolic consequences: implications for clinical practice. <i>Current Medical Research and Opinion</i> , 2008, 24, 609-624.	0.9	36
33	Review: Clinical aspects of the management of HIV lipodystrophy. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 113-119.	0.6	4
34	Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 887-898.	1.0	52
35	The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium&#x201c;lithium countertransporter1. <i>American Journal of Hypertension</i> , 2002, 15, 633-637.	1.0	10
36	Correction for the adverse influence of sodium&#x201c;potassium cotransport on apparent sodium&#x201c;lithium countertransport activity in human erythrocytes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2002, 47, 19-24.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. <i>American Journal of Hypertension</i> , 2001, 14, 32-37.	1.0	7
38	The current status of antihypertensive treatments: into the new millennium. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 731-737.	0.9	2
39	Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1098-1105.	1.0	1
40	Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. <i>European Journal of Clinical Pharmacology</i> , 2001, 56, 805-811.	0.8	9
41	Erythrocyte sodium-lithium countertransport in African American women. <i>Journal of Human Hypertension</i> , 2001, 15, 505-506.	1.0	2
42	Sodium-Lithium Countertransport Activity Is Linked to Chromosome 5 in Baboons. <i>Hypertension</i> , 2001, 38, .	1.3	0
43	Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. <i>Journal of Human Hypertension</i> , 2000, 14, 561-565.	1.0	1
44	Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. <i>Journal of Human Hypertension</i> , 1999, 13, 871-873.	1.0	0
45	Transport of phytanic acid on lipoproteins in Refsum disease. <i>Journal of Inherited Metabolic Disease</i> , 1999, 22, 29-36.	1.7	17
46	Na,Li-countertransport and ethnicity. <i>American Journal of Hypertension</i> , 1999, 12, 433-434.	1.0	0
47	Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with three other ethnic groups. <i>Journal of Human Hypertension</i> , 1998, 12, 29-34.	1.0	10
48	Characterization of the Erythrocyte Sodium-Lithium Countertransporter: Limitations and Assumptions of Traditional and Kinetic Methodologies. <i>Journal of Membrane Biology</i> , 1998, 161, 197-205.	1.0	5
49	Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. <i>European Journal of Clinical Investigation</i> , 1998, 28, 334-338.	1.7	2
50	F012 Triglycerides not insulin resistance principally determine sodium-lithium countertransport activity in patients with familial hyperchylomicronaemia. <i>American Journal of Hypertension</i> , 1998, 11, 156A.	1.0	0
51	Cation transport in Bartter's syndrome. <i>Journal of Hypertension</i> , 1998, 16, 549-551.	0.3	0
52	Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease. <i>American Journal of Hypertension</i> , 1996, 9, 184-187.	1.0	9
53	Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twins. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1203-1207.	1.5	4
54	Controversies surrounding erythrocyte sodium-lithium countertransport. <i>Journal of Hypertension</i> , 1996, 14, 695-703.	0.3	37

#	ARTICLE	IF	CITATIONS
55	Erythrocyte Sodium-Lithium Countertransport Activity in Non-Nephropathic Diabetic Twins. <i>Diabetes Care</i> , 1996, 19, 32-38.	4.3	5
56	Sodium-lithium countertransport and sodium-hydrogen exchange: the dual modality hypothesis Reply. <i>Journal of Hypertension</i> , 1996, 14, 1153-1154.	0.3	2
57	Exercise electrocardiography and aortic Doppler velocimetry in asymptomatic identical twins discordant for type 1 (insulin dependent) diabetes.. <i>Heart</i> , 1994, 71, 341-348.	1.2	1
58	Enoximone in Chronic Stable Angina: A Double-Blind Placebo-Controlled Cross-Over Trial. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 532-538.	0.8	2
59	Sodium-lithium countertransport activity is not affected by short-term insulin exposure in vivo or in a physiologic medium in vitro. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1087-1089.	1.5	11
60	Short papers in pharmaceutical analysis. <i>Analytical Proceedings</i> , 1993, 30, 361.	0.4	1
61	Erythrocyte sodium-lithium countertransport and blood pressure in identical twin pairs discordant for insulin dependent diabetes.. <i>BMJ; British Medical Journal</i> , 1992, 305, 215-219.	2.4	21
62	Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.. <i>F1000Research</i> , 0, 11, 259.	0.8	0